TGTX Stock Analysis: TG Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.744m USD | 12M Return: 41% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 143M
Qual. Beats: -2
Rev. Trend: 80.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
TG Therapeutics (NASDAQ: TGTX) is a U.S.-based commercial stage biopharmaceutical company incorporated in 1993 and headquartered in Morrisville, North Carolina. The company focuses on acquiring, developing, and commercializing novel therapies for B-cell mediated diseases, serving markets in the United States and internationally. Its lead marketed product is BRIUMVI, an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
The companys development pipeline centers on B-cell and immune-targeting mechanisms. It includes Ublituximab IV, a glycoengineered anti-CD20 monoclonal antibody for relapsing MS; TG-1701, an oral covalent Brutons tyrosine kinase (BTK) inhibitor; and TG-1801, a bispecific antibody targeting both CD47 and CD19. Anti-CD20 antibodies have become a cornerstone class in the treatment of multiple sclerosis and other autoimmune conditions, while BTK inhibitors represent an active area of drug development in immunology and oncology. The company also maintains a broader research pipeline of investigational medicines.
TG Therapeutics supplements its internal R&D with licensing arrangements, holding agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Jiangsu Hengrui Medicine Co. Such partnerships are a common strategy for mid-sized biotechnology companies seeking to broaden their pipelines and geographic reach without bearing full development costs.
- BRIUMVI sales accelerate in relapsing multiple sclerosis market
- Competition from Ocrevus and Kesimpta pressures CD20 market share
- TG-1701 BTK inhibitor pipeline data readout approaches
| Net Income: 461.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA 8.38 > 1.0 |
| NWC/Revenue: 128.5% < 20% (prev 125.3%; Δ 3.15% < -1%) |
| CFO/TA -0.01 > 3% & CFO -14.0m > Net Income 461.9m |
| Net Debt (247.5m) to EBITDA (150.2m): 1.65 < 3 |
| Current Ratio: 5.81 > 1.5 & < 3 |
| Outstanding Shares: last quarter (160.1m) vs 12m ago -1.66% < -2% |
| Gross Margin: 83.04% > 18% (prev 87.43%; Δ -4.38% > 0.5%) |
| Asset Turnover: 64.09% > 50% (prev 58.84%; Δ 5.25% > 0%) |
| Interest Coverage Ratio: 5.42 > 6 (EBIT TTM 149.9m / Interest Expense TTM 27.6m) |
| A: 0.59 (Total Current Assets 1.09b - Total Current Liabilities 187.1m) / Total Assets 1.53b |
| B: -0.69 (Retained Earnings -1.06b / Total Assets 1.53b) |
| C: 0.14 (EBIT TTM 149.9m / Avg Total Assets 1.09b) |
| D: 0.62 (Book Value of Equity 583.1m / Total Liabilities 945.7m) |
| Altman-Z'' = 3.17 = A |
| DSRI: 1.14 (Receivables 392.0m/190.1m, Revenue 700.3m/386.4m) |
| GMI: 1.05 (GM 87.43% / 83.04%) |
| AQI: 35.61 (AQ_t 0.28 / AQ_t-1 0.01) |
| SGI: 1.81 (Revenue 700.3m / 386.4m) |
| TATA: 0.31 (NI 461.9m - CFO -14.0m) / TA 1.53b) |
| Beneish M = 18.27 (Cap -4..+1) = D |
As of July 15, 2026, the stock is trading at USD 54.89 with a total of 2,029,897 shares traded. Over the past week, the price has changed by -5.46%, over one month by +9.13%, over three months by +58.83% and over the past year by +41.03%.
Current recommended Stop Loss: 52.00 (which is 5.3% or 1.1 ATR below the current price).
TG Therapeutics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy TGTX.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 52.1 | -5% |
P/E Trailing = 19.972
P/E Forward = 44.0529
P/S = 12.9094
P/B = 15.0266
P/EG = 1.6144
Revenue TTM = 700.3m USD
EBIT TTM = 149.9m USD
EBITDA TTM = 150.2m USD
Long Term Debt = 745.1m USD (from longTermDebt, last quarter)
Short Term Debt = 1.82m USD (from shortTermDebt, last quarter)
Debt = 762.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.42m
Net Debt = 247.5m USD (calculated: Debt 762.0m - CCE 514.4m)
Enterprise Value = 8.99b USD (8.74b + Debt 762.0m - CCE 514.4m)
Interest Coverage Ratio = 5.42 (Ebit TTM 149.9m / Interest Expense TTM 27.6m)
EV/FCF = -633.6x (Enterprise Value 8.99b / FCF TTM -14.2m)
FCF Yield = -0.16% (FCF TTM -14.2m / Enterprise Value 8.99b)
FCF Margin = -2.03% (FCF TTM -14.2m / Revenue TTM 700.3m)
Net Margin = 65.95% (Net Income TTM 461.9m / Revenue TTM 700.3m)
Gross Margin = 83.04% ((Revenue TTM 700.3m - Cost of Revenue TTM 118.7m) / Revenue TTM)
Gross Margin QoQ = 83.65% (prev 80.19%)
Tobins Q-Ratio = 5.88 (Enterprise Value 8.99b / Total Assets 1.53b)
Interest Expense / Debt = 3.63% (Interest Expense 27.6m / Debt 762.0m)
Taxrate = 2.88% (586k / 20.4m)
NOPAT = 145.6m (EBIT 149.9m * (1 - 2.88%))
Current Ratio = 5.81 (Total Current Assets 1.09b / Total Current Liabilities 187.1m)
Debt / Equity = 1.31 (Debt 762.0m / totalStockholderEquity, last quarter 583.1m)
Debt / EBITDA = 1.65 (Net Debt 247.5m / EBITDA 150.2m)
Debt / FCF = -17.44 (negative FCF - burning cash) (Net Debt 247.5m / FCF TTM -14.2m)
Total Stockholder Equity = 528.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 42.27% (Net Income 461.9m / Total Assets 1.53b)
RoE = 87.36% (Net Income TTM 461.9m / Total Stockholder Equity 528.7m)
RoCE = 11.77% (EBIT 149.9m / Capital Employed (Equity 528.7m + L.T.Debt 745.1m))
RoIC = 11.13% (NOPAT 145.6m / Invested Capital 1.31b)
WACC = 8.00% (E(8.74b)/V(9.51b) * Re(8.39%) + D(762.0m)/V(9.51b) * Rd(3.63%) * (1-Tc(0.03)))
Discount Rate = 8.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.71 | Cagr: 3.22%
[DCF] Fair Price = unknown (Cash Flow -14.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.00 | # QB: -2
Revenue Correlation: 80.76 | Revenue CAGR: 119.6% | SUE: 0.71 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=+0.94% | Revisions=+62% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=-0.93% | Revisions=+62% | Analysts=5
EPS current Year (2026-12-31): EPS=1.53 | Chg30d=-0.65% | Revisions=+40% | GrowthEPS=-44.9% | GrowthRev=+52.6%
EPS next Year (2027-12-31): EPS=3.01 | Chg30d=+4.80% | Revisions=+0% | GrowthEPS=+97.4% | GrowthRev=+32.1%
[Analyst] Revisions Ratio: +63% (up=14, down=2)